

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 23, 2002

By: Wendy Waters

#10
HP
6-1402
attachment

PATENT
Attorney Docket No. 20093A-002100US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Gerald P. Murphy *et al.*

JUN 05 2002

Examiner:

M. Schmidt

Application No.: 09/301,380

Art Unit:

1635

Filed: June 15, 2001

For: NR-CAM GENE, NUCLEIC
ACIDS AND NUCLEIC ACID
PRODUCTS FOR THERAPEUTIC AND
DIAGNOSTIC USES FOR TUMORS

**INFORMATION DISCLOSURE
STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed November 23, 2001, applicants submit herewith an Information Disclosure Statement.

Applicants direct the Examiner's attention to the references below, also listed on the accompanying Form PTO-1449. A copy of each is also enclosed.

The following articles are set forth in alphabetical order:

AA. Schwab, G. *et al.*, *An Approach for New Anticancer Drugs: Oncogene-Targeted Antisense DNA*, Annals of Oncology 5:55-58, 1994.

AB. Matveeva, O. *et al.*, *A Rapid In Vitro Method For Obtaining RNA Accessibility Patterns For Complementary DNA Probes: Correlation With An Intracellular Pattern and Known RNA Structures*, Nucleic Acids Res. 25:5010-6, 1997.

AC. Flanagan, Michael W., *Antisense Comes of Age*, Cancer and Metastasis Reviews 17:169-176, 1998.

AD. Ho, Siew Peng *et al.*, *Antisense Oligonucleotides for Target Validation in the CNS*, Current Opinion in Molecular Therapeutics 1:336-343, 1999.

AE. Holmlund, Jon T *et al.*, *Toward Antisense Oligonucleotide Therapy for Cancer: ISIS Compounds in Clinical Development*, Current Opinion in Molecular Therapeutics 1:372-385, 1999.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants believe that their invention as claimed is patentable over the above references taken alone or in any combination. However, Applicants reserve the right to demonstrate that their claimed invention was made prior to any one or more of the above-identified references. No inference should be drawn as to the pertinence of the references based on the order in which they are presented.

Applicants respectfully request that the Examiner review the foregoing references to make her own determination of the patentability of the present invention and that the references be made of record in the file of this application.

The Commissioner is hereby authorized to charge any fees necessitated by this transmittal to Townsend and Townsend Deposit Account No. 20-1430.

Respectfully submitted,

Dated: 23 May 2002

By: Brian W. Poor
Brian W. Poor
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111
Tel.: (206) 467-9600
Fax: (415) 576-0300